Outwitting Evolution - Progress Towards Clinical Xenotransplantation  by Cooper, David K.C.
The Journal of Surgery • Volume 1 • Issue 1 • 2003 9
Abstract
The critical and increasing shortage of human organs for
transplantation has stimulated much research into the
use of pig organs and cells in humans.  Previous clinical
experience with xenotransplantation is briefly reviewed.
Recent progress in overcoming the immunological 
and microbiological barriers is described, and the 
outstanding problems that remain in these areas and in
potential physiological incompatibilities are highlighted.
Consideration is given to the ethical, legal, regulatory,
and economic aspects of clinical xenotransplantation,
and also to the choice of the initial patients for early
clinical trials.  Finally, brief mention is made of potential
alternatives to xenotransplantation, such as artificial
organs, stem cell technology, and tissue engineering.
Abbreviations
AHXR = acute humoral xenograft rejection
CMV = cytomegalovirus
Gal = Gal1,3Gal
GT-KO = 1,3-galactosyltransferase gene-knockout
PERV = porcine endogenous retrovirus
Tx = transplantation
Background
Organ transplantation (Tx) was one of the great success
stories of the second half of the 20th century.  Indeed, it
is its very success that has led to the present crisis in
human donor organ supply1.  For example, in the UK,
there are 6,000 patients on the organ Tx waiting list but,
despite the fact that more than 10 million people are
registered with the UK Organ Donor Registry, in 2002
there were only 773 deceased donors who donated a
total of 2,644 organs.  In the USA, over 80,000 patients
currently await organ Tx, and yet less than 20,000
organs from deceased subjects will become available this
year.  The remaining unfortunate patients are likely to
die if they are in need of a heart or liver or, if awaiting 
a kidney, may have to remain on dialysis for at least 
another year. 
In addition, there are an estimated 100 million people in
the world with diabetes, several millions of whom are
dependent on insulin injections and who would benefit
from successful islet Tx.  There are many further millions
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with common degenerative conditions, such as
Parkinson’s disease, for whom neuronal cell Tx might
offer clinical improvement.  The number of islets and
neuronal cells that could be obtained from human
donors will never come close to meeting the potential
demand.
Xenotransplantation - in this case, the use of pig organs
and cells in humans1, 2 - would completely resolve the
problem of the supply of donor tissues.  There has
recently been some progress in research which has drawn
the prospect of unlimited pig organs and cells for Tx into
humans several steps closer.  
Early Clinical Trials
One has only to look at mythological animals, such as the
chimaera, to realize that xenoTx has been in the human
mind for centuries1.  Blood transfusions from animals
were not uncommon in the 17th and 18th centuries,
usually in an effort to improve the demeanor of those
prone to violent outbursts; sheep’s blood, coming from
such a docile animal, was considered to be particularly
effective in this respect.  Skin grafts, particularly from
frogs, were quite popular in the 19th century and, in the
1920s, a Russian Emigre surgeon, Serge Voronoff, 
working in Paris, carried out a series of testicle 
transplants from chimpanzees to aging men who had
lost their zest for life.  Testicle transplants were clearly
the ‘Viagra’ of the 1920s, some of the patients 
reportedly being ‘rejuvenated’ - presumably, a dramatic
placebo effect.  Although his efforts were ridiculed and
doomed to failure, Voronoff was, in fact, a visionary who
perceived an entirely new form of therapy, namely the
transplantation of cells to produce hormones in which
the patient was deficient. 
In the 1960-70s, several chimpanzee or baboon kidneys
and livers were transplanted into patients with terminal
organ failure, with one remarkable patient with a pair of
chimpanzee kidneys surviving for nine months3.
Chimpanzee, baboon, pig, and sheep hearts have all been
transplanted into patients since 1964, and two baboon
livers were transplanted in the early 1990s into patients
with chronic hepatitis B; in very few cases was survival
greater than a few days3.
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Choice of Pig as Organ-Source
For a number of reasons, largely logistic and ethical, it is
the pig, rather than the nonhuman primate, that has
been chosen as the potential source of organs and cells
for humans2, 4.  From the perspective of reproductive
capacity, growth, size, and so on, the pig has many
advantages over higher mammals.  It is, however, quite a
step further down the evolutionary scale than the 
primate.  For example, based on the reactivity of human
serum to albumin in the microcomplement fixation test,
if human serum albumin is arbitrarily scored as 1.0,
chimpanzee’s albumin would differ little (score 1.14), but
pig albumin is markedly different and would score >355.
In the words of Claus Hammer, an expert in this field,
what we are attempting to do in xenoTx is to ‘outwit
evolution’6, words I have taken for the title of this review.
Having decided to take on evolution, three major barri-
ers have been identified that must be overcome if the
pig is to become a successful source of organs for
humans, these are immunological, physiological and
microbiological. 
Immunological Barriers
‘Natural’ Antibodies
‘Natural’ (or ‘preformed’) antibodies (i.e., those that
develop in infancy following microbial colonisation of
the gastrointestinal tract) in humans and nonhuman 
primates are largely directed against galactose 
oligosaccharides, Gal1-3Gal (Gal), present on the 
surface of certain bacteria and viruses.  Unfortunately,
these T cell-independent Antibiotics crossreact with
identical Gal epitopes on pig vascular endothelium.
These anti-Gal antibodies form the major component of
the initial primate immune response against transplant-
ed pig organs7, 8.  Their binding to Gal epitopes activates
complement, which leads to the hyperacute rejection
(within minutes or hours) of the transplanted pig organ.  
This problem has now been overcome by a number of
different approaches9, including the use of a 
transgenic pig organ expressing a human complement
regulatory protein, such as decay-accelerating factor
Figures 1 and 2, that protects it from injury mediated by
human complement10.  However, the return or continu-
ing presence of anti-Gal antibodies ultimately leads to a
delayed form of antibody-mediated rejection, acute
humoral xenograft rejection (AHXR), that does not
appear to be dependent on activation of complement11.
Elicited Antibodies 
To compound the problem of natural antibody, the Tx of
a pig organ or cells into a nonhuman primate leads to a
T cell-dependent elicited antibody response that
includes a 100-fold increase in anti-Gal antibody, 
particularly of IgG, together with the development 
of antibodies to new (nonGal) pig targets12.
Natural antibodies alone appear to be sufficient to cause
AHXR, but the production of elicited antibodies 
accelerates its development.  Even though the elicited
antibody response can be prevented by therapy directed
at suppressing T lymphocyte activation13, AHXR has not
been completely overcome to date, even though 
survival of pig organs in nonhuman primates for more
than three months has been achieved14.
Figure 1: Microinjection of a human gene into a pig egg,
performed under the microscope. This technique was
used to inject the gene for human decay-accelerating
factor that partially protected the pig’s organs 
from rejection associated with antibody-mediated 
complement activation after transplantation, 
and resulted in increased survival. The diameter of the
egg is approximatley 0.07mm and that of the injection
pipette (on the right) approximatley 0.00075mm
Figure 2: Major steps in breeding a transgenic pig.
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The Newest Breakthrough 
In 1993, it was suggested that the problem of anti-Gal
antibody-mediated destruction of pig organs could be
overcome if pigs did not express Gal antigens, and that
this could be achieved by ‘knocking-out’ the gene that 
encodes the enzyme that is responsible for the 
production of Gal molecules (1,3-galactosyltransferase);
such a “GT-KO” pig would not express Gal epitopes15.
This approach was not possible in pigs at that time but,
with the introduction of the technique of nuclear 
transfer in 199616, 17, it became feasible (Figure 3).
Deletion of the gene in a cell by homologous 
recombination, and the use of nuclear transfer 
technology to develop an animal from that modified
cell, enabled GT-KO pigs to be bred in 200218, 19.
Since pigs express high levels of Gal, which was thought
perhaps to be physiologically essential, there had been
concern that GT-KO pigs might not be viable, but these
pigs are reported to be healthy.  
With the availability of GT-KO pigs, the anti-Gal 
antibody problem will be overcome. With the ability of
some immunosuppressive regimens to prevent the 
elicited anti-(nonGal) pig antibody response, perhaps it
is not too optimistic to say that the major problem that
has been faced for the past decade might appear to be
largely resolved. 
Cellular Responses
With the immunosuppressive therapy that has been
administered to try to prevent AHXR, T cell-mediated
acute cellular rejection (similar to that seen in alloTx) has
been uncommon, and has not been a major cause of
graft failure.  However, if prolonged graft survival can be
achieved, it is likely that chronic rejection (e.g., in the
form of graft vasculopathy) will occur more readily and
at an earlier stage in a xenograft than in an allograft, but
there are virtually no data on this as yet. 
Physiological Barriers
Hammer6, 20 has long been warning the xenotransplant
community that physiologic incompatibilities between
pigs and humans may prove a significant 
problem in progressing towards successful clinical
xenoTx.  From animal studies, however, there is evidence
that the pig kidney can support life for almost three
months in a nonhuman primate14, although anemia
develops, thought to be related to the fact that pig 
erythropoietin does not function satisfactorily in 
primates21.  The pig heart has functioned satisfactorily in
the heterotopic position in baboons and monkeys for
periods of up to four months14, and orthotopically in one
baboon for 39 days22.
There is optimism, therefore, that both the pig kidney
and heart may function adequately in humans 
long-term if the immunologic problems can be 
overcome.  However, the synthetic products of the pig
liver are unlikely to be identical to those of the human
liver and, therefore, after a pig liver transplant, some
enzymes and hormones may not function in the human
recipient6, 20.  Genetic engineering of the pig to enable its
liver to produce essential human products may be
required. 
Most current concern relates to incompatibilities in
coagulation factors between pig and human that may
result in a procoagulant (rather than the normal 
anticoagulant) state on the vascular endothelium of the
transplanted pig organ23, 24, possibly progressing to 
intra-graft thrombosis or inducing disseminated
intravascular coagulation.  These incompatibilities may
be accentuated by activation of the vascular 
endothelium of the transplanted pig organ by antibody
deposition or by viral infection (see below). 
The administration of heparin or antithrombin III can
delay this occurrence to some extent, but neither agent
could be administered indefinitely in the clinical 
situation. The introduction into the donor pig of human
genes that may maintain an anticoagulant state on the
vascular endothelium may be required.   
Microbiological Barriers
Pigs can be bred and housed under relatively clean 
conditions, and appropriate animal husbandry is likely to
lead to pigs that are free of most bacteria and fungi, 
and many exogenous viruses25.  For example, 
early weaning of piglets from the sow and their isolation
from cytomegalovirus (CMV)-seropositive animals results
Figure 3: Major steps in technique of nuclear transfer
(cloning). The donor of the nuclear material (Pig 1) 
is usually an embryo or fetus rather than an adult pig.
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in their remaining CMV-seronegative (Mueller, N., et al,
manuscript submitted).  There is relative optimism that
many, though not all, exogenous viruses could be 
eliminated from organ-source pigs by such means. 
This may be important not only from a safety 
perspective, but also because it has recently been
demonstrated in vitro that CMV infection of pig aortic
endothelial cells leads to changes indicative of a 
procoagulant state that may accelerate the thrombus
formation that occurs in the vessels of the grafted organ 
The genome of all pig cells contains porcine endogenous
retroviruses (PERV), just as the nuclei of human cells
contain human endogenous retroviruses25, 26.  Although
the human and pig endogenous retroviruses appear to
do their respective hosts no harm, there is 
concern that infection of human cells by PERV, 
which can certainly occur in vitro, may lead to the
development of a new infection in humans.  The form
this would take remains uncertain, but would possibly be
oncogenic or give rise to an immune-deficiency state.
However, there has been no evidence to date of such
infection in vivo in humans or nonhuman primates
exposed to living pig cells or organs27.  Furthermore, the
PERV of some pigs appear unable to infect human cells
in co-culture studies28; if this proves to be the case in
vivo, then although the transplanted organ will contain
PERV, the human recipient’s tissues will not be infected,
and the recipient will not be a source of infection to
other humans.
Ethical, Legal and Regulatory Aspects
Some ethical questions relate to the patient - informed
consent, patient confidentiality, and so on1, 29.  Others
relate to animal welfare and rights - for example, 
how much genetic manipulation of a pig is ethical or, in
other words, when is a pig no longer a pig?  It should not
be forgotten, however, that there are current concerns
relating to the Tx of human organs, such as the 
potential risks to which living liver donors are exposed,
and the abuse of human rights in certain countries
where prisoners are executed and their organs sold for
Tx; xenoTx will remove the need for human organs.  
Legal questions are also being asked1, 30.  For example, if
a patient contracts a pig infection and transfers it to an
acquaintance, will the acquaintance be able to sue for
compensation and, if so, who could be sued - patient,
surgeon, hospital, or pig breeder?  In view of the 
potential for the patient to become a danger to the 
public health, there have been calls, not least from those
researching this field, for governmental regulation of
clinical xenoTx, and various guidelines have been 
published1, 31, 32.  Despite these ethical and legal 
concerns, polls in various countries indicate that 
approximately 50% of the public support the concept of
xenoTx.  If this form of surgical therapy could be 
demonstrated to be life-saving, however, public support
is likely to rapidly increase.  Enthusiasm for the Tx of
human organs was equally lukewarm in the early days
before it became successful.  
The Economics of Clinical
Xenotransplantation
Organ Tx accounts for less than 0.5% of health care
expenditure in the developed world, although this is not
an inconsiderable sum of money (estimated to be
approximately US$10 billion)1.  If xenoTx can be proved
life-saving, the number of organ transplants 
performed will increase perhaps four- or five-fold,
resulting in increased expenditure.  Although the costs
will be offset to some considerable extent by savings on
other forms of therapy, such as dialysis or the intensive
care of patients with terminal heart or liver failure while
they await a human organ, nevertheless, overall 
expenditure is likely to increase.  It will be for society to
decide whether it wishes to accept this added financial
burden for the sake of those who will benefit. 
Choice of Initial Patients
Several clinical trials of islet and neuronal cell xenoTx
have been undertaken during the past decade or so1, 33, 34
and cell or tissue transplants, because of their relatively
low risk to the patient, are likely to continue to be
among the early trials of xenoTx.  With regard to 
clinical organ xenoTx, patients requiring kidneys would
have the advantage that, if the pig graft were rejected,
a return to dialysis might be possible.  An alternative
would be to use a pig heart or liver as a temporary
‘bridge’ to maintain life for a few days or weeks until a
human organ became available; although this approach
would do nothing to reduce the waiting list for human
organs, it would provide valuable clinical experience
with xenoTx and be a ‘stepping-stone’ to the permanent
placement of pig organs.
Alternatives to Xenotransplantation
Mechanical devices that assist the heart are currently in
a much more advanced state of development than
xenoTx, and have supported patients awaiting heart Tx
for a year or more in some instances. But devices have
their own problems, and a well-functioning natural
heart, even a pig’s, would almost certainly be preferable
to any mechanical device.  Furthermore, we are not close
to developing an implantable artificial kidney, liver or
lung that could function long-term.  
The ability of human stem cells to transform into, for
example, cardiomyocytes, that could be used to 
augment cardiac function, has received much recent
attention, but there is an immense amount of research
and development to be done before a stem cell can be
programmed to provide an entire organ, with all its 
specialized cells that have to function in a coordinated
fashion.  With the pig, we already have that organ.
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However, the ability of human stem cells to provide large
numbers of a single type of cell, for example, in the form
of pancreatic islets, may be of potential clinical 
application within the foreseeable future.  Tissue 
engineering is another potential solution for the need
for specific human cells, but the growth of an entire
organ would appear to be only a distant prospect.
Immediate Prospects?
With the availability of GT-KO pigs and of 
immunosuppressive agents that prevent the elicited
antibody response, the immunologic problems of xenoTx
will be reduced significantly.  There is now less concern
over transfer of PERV than hitherto, but potential 
infection with exogenous viruses requires further 
investigation, as do the physiologic aspects of xenoTx,
particularly those relating to coagulation pathways. 
One can cautiously predict, however, that clinical xenoTx
will be introduced in the foreseeable future, but exactly
when that will be remains uncertain.  In the words of
transplant pioneer, Sir Roy Calne, spoken as long ago as
1995, “Clinical xenotransplantation is just around the
corner, but it may be a very long corner.”
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